“Innovative Strategies for Replacing IVIg in Autoimmune Disease: The Role of Fc Receptor Blockade.”

DR. ALAN LAZARUS

Professor, Departments of Medicine and Laboratory Medicine, University of Toronto
Senior Scientist, Canadian Blood Services
Scientist, St. Michael’s Hospital (Unity Health)

IVIG, a long-established treatment for autoimmune and inflammatory conditions involving IgG and FcγRs, faces serious supply constraints. Our research delves into IVIG’s mechanisms, highlighting the potential of FcγR blockade as a lab-made IVIG substitute, as demonstrated in FcγR-humanized mice. This recent work offers promising avenues for enhancing treatment accessibility and efficacy.